⚡ Flash Summary

GlaxoSmithKline (GSK) Pakistan Limited’s report for the nine months ended September 30, 2025, shows a net sales of Rs. 44.5 billion, which includes Rs. 0.88 billion from Haleon Pakistan Limited. Excluding these specific sales, the underlying sales growth is 3.4%. The gross margin increased to 35.8%, a 14% increase due to price adjustments and profitability measures. Earnings per share increased significantly from Rs. 11.25 to Rs. 19.57. Despite signs of economic stabilization in Pakistan, risks remain, including rising inflation and fiscal challenges.

📌 Key Takeaways

• 📈 Net sales reached Rs. 44.5 billion.
• 📉 Haleon Pakistan Limited contributed Rs. 0.88 billion compared to Rs. 1.42 billion last year.
• 🌱 Underlying sales growth, excluding Haleon, is 3.4%.
• 📊 Gross margin increased to 35.8%, up 14% from the previous period.
• 💰 Earnings per share (EPS) jumped to Rs. 19.57 from Rs. 11.25.
• ⬆️ Operating expenses increased modestly, by 1.6% relative to sales.
• 🌍 Pakistan’s economy shows signs of stabilization with 2.7% GDP growth.
• ⚠️ Risks remain due to inflation, fiscal challenges, and climate vulnerability.
• 🤝 Company focuses on stakeholder collaboration and cost-saving strategies.
• 🔬 Commitment to high-quality medicines and improved profitability.
• 🌱 Investments in key business drivers for competitive growth.
• 🌊 Recent floods highlight climate change vulnerability.

🎯 Investment Thesis

HOLD. The company shows improved performance in key areas like gross margin and EPS, but potential economic instability and regulatory uncertainty in Pakistan create headwinds. Current financials do not clearly indicate an under or over valuation.